Literature DB >> 29296024

Behçet syndrome: a contemporary view.

Hasan Yazici1, Emire Seyahi2, Gulen Hatemi2, Yusuf Yazici3.   

Abstract

The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn's disease suggest multiple pathological pathways are involved in Behçet syndrome. These features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 to be the important genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bone fide disease, especially in non-endemic regions, suggests other factors must also be operative in Behçet syndrome. This consideration is also true for the newly proposed 'MHC-I-opathy' concept. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease (such as Budd-Chiari syndrome and pulmonary artery involvement), eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behçet syndrome, including those with eye disease, continue to improve.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29296024     DOI: 10.1038/nrrheum.2017.208

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  116 in total

Review 1.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

2.  Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity.

Authors:  Michael J Ombrello; Yohei Kirino; Paul I W de Bakker; Ahmet Gül; Daniel L Kastner; Elaine F Remmers
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

3.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 4.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.

Authors:  Ahmet Gül; Ilknur Tugal-Tutkun; Charles A Dinarello; Leonid Reznikov; Bahar Artim Esen; Amer Mirza; Patrick Scannon; Alan Solinger
Journal:  Ann Rheum Dis       Date:  2011-11-14       Impact factor: 19.103

6.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

Review 7.  Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?

Authors:  Carmen Ambarus; Nataliya Yeremenko; Paul P Tak; Dominique Baeten
Journal:  Curr Opin Rheumatol       Date:  2012-07       Impact factor: 5.006

8.  FUT2: filling the gap between genes and environment in Behçet's disease?

Authors:  Joana M Xavier; Farhad Shahram; Inês Sousa; Fereydoun Davatchi; Mafalda Matos; Bahar Sadeghi Abdollahi; João Sobral; Abdolhadi Nadji; Manuela Oliveira; Fahmida Ghaderibarim; Niloofar Mojarad Shafiee; Sofia A Oliveira
Journal:  Ann Rheum Dis       Date:  2013-12-10       Impact factor: 19.103

Review 9.  Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.

Authors:  Alban Deroux; Chistophe Chiquet; Laurence Bouillet
Journal:  Semin Arthritis Rheum       Date:  2015-12-02       Impact factor: 5.532

10.  The oral mucosal and salivary microbial community of Behçet's syndrome and recurrent aphthous stomatitis.

Authors:  Noha Seoudi; Lesley A Bergmeier; Francis Drobniewski; Bruce Paster; Farida Fortune
Journal:  J Oral Microbiol       Date:  2015-06-01       Impact factor: 5.474

View more
  64 in total

1.  Peripheral blood mononuclear cell proteome profile in Behçet's syndrome.

Authors:  Asli Kirectepe Aydin; Yeşim Özgüler; Didar Uçar; Murat Kasap; Gürler Akpınar; Emire Seyahi; Eda Tahir Turanli
Journal:  Rheumatol Int       Date:  2019-08-14       Impact factor: 2.631

2.  Budd-Chiari Syndrome in Behçet's Disease successfully managed with immunosuppressive and anticoagulant therapy: A case report and literature review.

Authors:  Christian Mario Amodeo Oblitas; Francisco Galeano-Valle; Neera Toledo-Samaniego; Blanca Pinilla-Llorente; Jorge Del Toro-Cervera; Arturo Álvarez-Luque; Alejandra García-García; Pablo Demelo-Rodriguez
Journal:  Intractable Rare Dis Res       Date:  2019-02

3.  Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics.

Authors:  Jurgen Sota; Donato Rigante; Giacomo Emmi; Giuseppe Lopalco; Ida Orlando; Gian Marco Tosi; Bruno Frediani; Antonio Vitale; Silvana Guerriero; Florenzo Iannone; Lorenzo Vannozzi; Claudia Fabiani; Luca Cantarini
Journal:  Intern Emerg Med       Date:  2020-02-01       Impact factor: 3.397

4.  Hemoptysis in Behçet's syndrome: from bedside to bench?

Authors:  Giovanni Maria Rossi; Giacomo Emmi; Augusto Vaglio
Journal:  Intern Emerg Med       Date:  2018-05-07       Impact factor: 3.397

Review 5.  Pediatric Behçet's disease - clinical aspects and current concepts.

Authors:  Mehmet Yıldız; Oya Köker; Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Eur J Rheumatol       Date:  2019-09-05

Review 6.  Behçet's Syndrome and Nervous System Involvement.

Authors:  Uğur Uygunoğlu; Aksel Siva
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 7.  Optic neuritis as a presenting feature of Behçet's disease: case-based review.

Authors:  Željka Kardum; Jasminka Milas Ahić; Ana Marija Lukinac; Ružica Ivelj; Višnja Prus
Journal:  Rheumatol Int       Date:  2020-08-29       Impact factor: 2.631

8.  Prevalence and demographic characteristics of Behcet disease in Colombia: data from the national health registry 2012-2016.

Authors:  Daniel G Fernández-Ávila; Diana N Rincón-Riaño; Santiago Bernal-Macías; Juan M Gutiérrez Dávila; Diego Rosselli
Journal:  Rheumatol Int       Date:  2019-10-29       Impact factor: 2.631

Review 9.  Triggering agents and microbiome as environmental factors on Behçet's syndrome.

Authors:  Gonca Mumcu; Haner Direskeneli
Journal:  Intern Emerg Med       Date:  2018-12-06       Impact factor: 3.397

10.  Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Behçet's disease.

Authors:  Giuseppe Lopalco; Vincenzo Venerito; Luca Cantarini; Giacomo Emmi; Domenico Prisco; Florenzo Iannone
Journal:  Intern Emerg Med       Date:  2018-10-25       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.